Company Filing History:

14 out of 4,770

Merck + Co., Inc.

patents

1 out of 512

Sloan-kettering Institute for Cancer Research

patents

Years Active: 1990-2006

Loading Chart...

15 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 6989383 - Method of treating cancer (2006-01-24),

2. 6391305 - Conjugates useful in the treatment of prostate cancer (2002-05-21),

3. 6207798 - Modified PE40 toxin fusion proteins (2001-03-27),

4. 6177404 - Conjugates useful in the treatment of benign prostatic hyperplasia (2001-01-23),

5. 6143864 - Peptides (2000-11-07),

6. 6130204 - Peptides (2000-10-10),

7. 5866679 - Peptides (1999-02-02),

8. 5690928 - Method of treating bladder cancer cells (1997-11-25),

9. 5599686 - Peptides (1997-02-04),

10. 5473056 - E2F-2, a novel mammalian transcription factor (1995-12-05),

11. 5047502 - Gastrin releasing peptide antagonist (1991-09-10),

12. 5028692 - Gastrin releasing peptide antagonist (1991-07-02),

13. 5019647 - Gastrin releasing peptide antagonist (1991-05-28),

14. 4943561 - Gastrin releasing peptide antagonist (1990-07-24),

15. 4923878 - Quinolizine sulfonamides used against certain neoplastic disease states (1990-05-08),

Title: The Innovative Contributions of Allen I Oliff

Introduction

Allen I Oliff is a notable inventor based in Gwynedd Valley, PA (US), recognized for his significant contributions to cancer treatment. With a total of 15 patents, his work has advanced the field of oncology and provided new avenues for therapeutic interventions.

Latest Patents

Among his latest patents, one notable invention is a method of treating cancer. This invention relates to methods that utilize a combination of an antineoplastic agent and an inhibitor of prenyl-protein transferase. The methods involve administering these therapeutic agents either sequentially or simultaneously to achieve effective treatment outcomes. Another significant patent involves chemical conjugates useful in the treatment of prostate cancer. These conjugates consist of oligopeptides that are selectively cleaved by free prostate-specific antigen (PSA), along with hydrophilic blocking groups and known cytotoxic agents. This innovation aims to enhance treatment efficacy for prostatic cancer and benign prostatic hypertrophy (BPH).

Career Highlights

Throughout his career, Allen I Oliff has worked with prestigious organizations, including Merck & Company, Inc. and the Sloan-Kettering Institute for Cancer Research. His experience in these institutions has allowed him to collaborate with leading experts in the field and contribute to groundbreaking research.

Collaborations

Some of his notable coworkers include Victor M Garsky and Raymond E Jones. Their collaborative efforts have further enriched the research landscape in cancer treatment.

Conclusion

Allen I Oliff's innovative work and dedication to cancer research have made a lasting impact on the field. His patents reflect a commitment to improving therapeutic strategies and enhancing patient outcomes.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com

Inventor’s Patent Attorneys refers to legal professionals with specialized expertise in representing inventors throughout the patent process. These attorneys assist inventors in navigating the complexities of patent law, including filing patent applications, conducting patent searches, and protecting intellectual property rights. They play a crucial role in helping inventors secure patents for their innovative creations.